Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia

Inclusion Criteria:

• Age ≥18 years

• Hospitalized in ICU

• Presence of all of the following conditions, within one week of a clinical insult ornew or worsening respiratory symptoms:

• PaO2/FiO2 <300 mmHg with positive end-expiratory pressure (PEEP) ≥5 cmH2O

• Bilateral opacities not fully explained by cardiac failure or fluid overload

• Intubated and sedated for mechanical protective ventilation

• Affiliation to the French Sociale security

• Beta HCG negative for women

For Covid-19 subgroup:

• Covid-19 infection (RT-PCR < 7 days and/or another approved diagnostic techniqueand/or typical CT appearance of COVID-19 pneumonia

Exclusion Criteria:

• Allergy to amide local anesthetics

• Acute porphyria

• Disorders of atrioventricular conduction requiring a non-done permanentelectrosystolic pacing

• Uncontrolled epilepsy

• Fluvoxamine treatment

• Class III antiarrythmic agent treatments (amiodarone, dronedarone)

• Class I antiarythmic agent (quinidine, disopyramide, hydroquinidine, flecainid,propafenone)

• Hepatocellular insufficiency defined by PT<15% in the absence of anti-vitamin K

• Patient under a tutelage measure or placed under judicial protection

• Known pregnancy

• Breastfeeding